|
FY2025
12 months to Apr 30, 2025
|
FY2024
12 months to Apr 30, 2024
|
FY2023
12 months to Apr 30, 2023
|
FY2022
12 months to Apr 30, 2022
|
FY2021
12 months to Apr 30, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Sales of uranium inventory | |||||
| Royal revenue | |||||
| Cost of sales | |||||
| Cost of uranium inventory | |||||
| Depletion | |||||
| Gross profit | |||||
| Expenses | |||||
| Depreciation | |||||
| Consulting fees | |||||
| Management and directors' fees | |||||
| Salaries, wages and benefits | |||||
| Uranium storage fee | |||||
| Investor communications and marketing expenses | |||||
| Office and technology expenses | |||||
| Salaries and directors' fees | |||||
| Office and administration | |||||
| Professional fees and insurance | |||||
| Transfer agent and regulatory fees | |||||
| Insurance fees | |||||
| Professional fees | |||||
| Write-off of royalty option | |||||
| Share-based compensation | |||||
| Operating income (loss) for the year | |||||
| Other items | |||||
| Other income | |||||
| Finance cost | |||||
| Interest expense | |||||
| Interest income | |||||
| Gain on sale of marketable securities | |||||
| Net foreign exchange loss | |||||
| Income (loss) before taxes | |||||
| Deferred income tax recovery (expense) | |||||
| Net income (loss) for the year | |||||
| Other comprehensive income (loss) | |||||
| Items that will not subsequently be re-classified to net income (loss): | |||||
| Gain (loss) on revaluation of short-term investments | |||||
| Deferred tax recovery (expense) on short-term investments | |||||
| Item that may subsequently be re-classified to net income: | |||||
| Foreign currency translation differences | |||||
| Total other comprehensive income (loss) for the year | |||||
| Total comprehensive income (loss) for the year | |||||
| Net loss per share, basic and diluted | |||||
| Basic earnings (loss) per share | |||||
| Diluted earnings (loss) per share | |||||
| Weighted average number of shares outstanding, Basic | |||||
| Weighted average number of shares outstanding, Diluted | |||||
Loading...